Prevail Innovative Wealth Advisors LLC Purchases New Stake in Danaher Co. (NYSE:DHR)

Prevail Innovative Wealth Advisors LLC acquired a new position in shares of Danaher Co. (NYSE:DHR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,416 shares of the conglomerate’s stock, valued at approximately $3,768,000. Danaher comprises approximately 1.1% of Prevail Innovative Wealth Advisors LLC’s holdings, making the stock its 26th largest holding.

A number of other hedge funds also recently modified their holdings of DHR. Heck Capital Advisors LLC purchased a new position in shares of Danaher in the fourth quarter worth about $27,000. Decker Retirement Planning Inc. purchased a new stake in Danaher during the fourth quarter valued at about $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter valued at about $31,000. Strategic Financial Concepts LLC bought a new stake in Danaher in the 4th quarter worth approximately $31,000. Finally, Pineridge Advisors LLC grew its position in Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 57 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

NYSE DHR opened at $205.69 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $147.01 billion, a P/E ratio of 38.96, a PEG ratio of 2.66 and a beta of 0.82. The company has a 50-day moving average price of $214.57 and a 200-day moving average price of $236.64. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the firm earned $2.09 EPS. Equities research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. Danaher’s payout ratio is 24.24%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $277.00 price target (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. The Goldman Sachs Group raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price objective for the company in a research note on Friday, March 21st. Raymond James restated a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Citigroup cut their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Robert W. Baird decreased their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.24.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.